FREDUN Q1 FY27 results at a glance
Fredun Pharmaceuticals Limited Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹228 cr |
|---|
| Revenue YoY | +90.7% |
|---|
| Operating profit | ₹29.17 cr |
|---|
| Operating margin | 12.8% |
|---|
| Net profit | ₹13.13 cr |
|---|
| Net profit YoY | +94.1% |
|---|
| Net profit QoQ | +21.8% |
|---|
| Net margin | 5.8% |
|---|
| Basic EPS | ₹7.94 |
|---|
| TTM revenue | ₹742 cr |
|---|
| TTM net profit | ₹43.82 cr |
|---|
| TTM net margin | 5.9% |
|---|
FREDUN Q1 FY27 results: what the numbers say
Fredun Pharmaceuticals Limited (FREDUN) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹228 cr and a net profit of ₹13.13 cr, translating into earnings per share of ₹7.94.
Compared with the same quarter a year earlier, revenue grew sharply by +90.7% and net profit grew sharply by +94.1%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹29.17 cr, an operating margin of 12.8% versus 13.0% a year ago — a contraction of 0.2 percentage points.
FREDUN quarter-wise results table
Net profit
₹13.13 cr
+94.1% YoY
Operating profit
₹29.17 cr
+87.3% YoY
Fredun Pharmaceuticals Limited (FREDUN) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹228 cr | ₹29.17 cr | ₹13.13 cr | 12.8% | 5.8% | ₹7.94 | +94.1% | +21.8% |
| Q4 FY262026-03-31 | ₹210 cr | ₹25.73 cr | ₹10.78 cr | 12.2% | 5.1% | ₹6.57 | — | +2.9% |
| Q3 FY262025-12-31 | ₹160 cr | ₹24.55 cr | ₹10.48 cr | 15.4% | 6.6% | ₹7.40 | — | +11.1% |
| Q2 FY262025-09-30 | ₹144 cr | ₹20.44 cr | ₹9.43 cr | 14.2% | 6.6% | ₹6.66 | — | +39.4% |
| Q1 FY262025-06-30 | ₹119 cr | ₹15.57 cr | ₹6.77 cr | 13.0% | 5.7% | ₹4.78 | — | — |
| TTM (last 4 quarters) | ₹742 cr | ₹99.89 cr | ₹43.82 cr | 13.5% | 5.9% | ₹28.56 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
FREDUN quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
Fredun Pharmaceuticals Limited quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹228 cr | ₹210 cr | ₹160 cr | ₹144 cr | ₹119 cr |
|---|
| Total expenses | ₹199 cr | ₹185 cr | ₹135 cr | ₹123 cr | ₹104 cr |
|---|
| Gross profit | ₹51.57 cr | ₹54.31 cr | ₹45.92 cr | ₹36.25 cr | ₹32.1 cr |
|---|
| Operating profit (EBIT) | ₹29.17 cr | ₹25.73 cr | ₹24.55 cr | ₹20.44 cr | ₹15.57 cr |
|---|
| Operating margin | 12.8% | 12.2% | 15.4% | 14.2% | 13.0% |
|---|
| Interest cost | ₹8.62 cr | ₹14.49 cr | ₹10.55 cr | ₹7.73 cr | ₹6.53 cr |
|---|
| Profit before tax | ₹20.55 cr | ₹11.25 cr | ₹14 cr | ₹12.71 cr | ₹9.04 cr |
|---|
| Tax expense | ₹7.42 cr | ₹0.47 cr | ₹3.52 cr | ₹3.27 cr | ₹2.27 cr |
|---|
| Effective tax rate | 36.1% | 4.2% | 25.2% | 25.8% | 25.2% |
|---|
| Net profit (PAT) | ₹13.13 cr | ₹10.78 cr | ₹10.48 cr | ₹9.43 cr | ₹6.77 cr |
|---|
| Net profit margin | 5.8% | 5.1% | 6.6% | 6.6% | 5.7% |
|---|
| Basic EPS | ₹7.94 | ₹6.57 | ₹7.40 | ₹6.66 | ₹4.78 |
|---|
| Diluted EPS | ₹7.40 | ₹6.07 | ₹7.40 | ₹6.66 | ₹0.00 |
|---|
FREDUN results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +90.7% | — | — | — | — |
|---|
| Revenue QoQ | +8.2% | +31.6% | +11.4% | +20.3% | — |
|---|
| Operating profit YoY | +87.3% | — | — | — | — |
|---|
| Operating profit QoQ | +13.4% | +4.8% | +20.1% | +31.2% | — |
|---|
| Net profit YoY | +94.1% | — | — | — | — |
|---|
| Net profit QoQ | +21.8% | +2.9% | +11.1% | +39.4% | — |
|---|
| EPS YoY | +66.2% | — | — | — | — |
|---|
| EPS QoQ | +20.9% | -11.2% | +11.1% | +39.4% | — |
|---|
FREDUN annual results history
Full-year performance for Fredun Pharmaceuticals Limited, useful for reading each quarter in context.
Fredun Pharmaceuticals Limited annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹633 cr | ₹452 cr | ₹347 cr | ₹274 cr |
|---|
| Total expenses | ₹539 cr | ₹395 cr | ₹312 cr | ₹249 cr |
|---|
| Gross profit | ₹169 cr | ₹106 cr | ₹72.98 cr | ₹56.91 cr |
|---|
| Operating profit (EBIT) | ₹94.22 cr | ₹56.63 cr | ₹34.2 cr | ₹24.99 cr |
|---|
| Operating margin | 14.9% | 12.5% | 9.9% | 9.1% |
|---|
| Interest cost | ₹37.49 cr | ₹20.42 cr | ₹12.52 cr | ₹7.56 cr |
|---|
| Profit before tax | ₹47 cr | ₹27.49 cr | ₹21.45 cr | ₹17.51 cr |
|---|
| Tax expense | ₹14.38 cr | ₹7.75 cr | ₹5.83 cr | ₹6.7 cr |
|---|
| Effective tax rate | 30.6% | 28.2% | 27.2% | 38.3% |
|---|
| Net profit (PAT) | ₹32.62 cr | ₹19.74 cr | ₹15.62 cr | ₹10.81 cr |
|---|
| Net profit margin | 5.2% | 4.4% | 4.5% | 3.9% |
|---|
| Basic EPS | ₹0.00 | ₹0.00 | ₹11.22 | ₹8.04 |
|---|
| Diluted EPS | ₹0.00 | ₹0.00 | ₹11.11 | ₹7.64 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹228 cr against ₹119 cr in Q1 FY26, and ₹210 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +8.2%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹199 cr, or 87.2% of revenue, with operating profit grew +87.3% year on year.
Margins, tax and profitability
Net profit of ₹13.13 cr works out to a net margin of 5.8% compared with 5.7% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, Fredun Pharmaceuticals Limited reported profit before tax of ₹20.55 cr, a tax charge of ₹7.42 cr (effective rate 36.1%), interest cost of ₹8.62 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹10.78 cr in Q4 FY26 to ₹13.13 cr in Q1 FY27, a change of +21.8%.
Trailing twelve months and annual context
Across the trailing four quarters Fredun Pharmaceuticals Limited has generated revenue of ₹742 cr and net profit of ₹43.82 cr, a trailing net margin of 5.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹633 cr with net profit of ₹32.62 cr and EPS of ₹0.00, versus the prior year where revenue grew +40.2% and profit grew +65.3%.
What to watch in the next FREDUN quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
Fredun Pharmaceuticals Limited has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
FREDUN results coverage
FREDUN quarterly results FAQs
What were Fredun Pharmaceuticals Limited (FREDUN) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), Fredun Pharmaceuticals Limited reported revenue of ₹228 cr and net profit of ₹13.13 cr, a change of +94.1% year on year on +90.7% revenue growth. EPS stood at ₹7.94.
What is FREDUN profit margin in Q1 FY27?
Fredun Pharmaceuticals Limited posted a net profit margin of 5.8% and an operating margin of 12.8% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹742 cr and net profit ₹43.82 cr.
Did FREDUN results beat the previous quarter?
Fredun Pharmaceuticals Limited net profit changed +21.8% quarter on quarter, from ₹10.78 cr in Q4 FY26 to ₹13.13 cr in Q1 FY27.
When are Fredun Pharmaceuticals Limited (FREDUN) quarterly results?
Fredun Pharmaceuticals Limited has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see FREDUN latest quarterly results?
Our latest FREDUN results coverage — "778% Multibagger! Fredun Pharmaceuticals Near Record High After Strong Q1 FY27 Results" — breaks down revenue, profit, margins and management commentary.
What is Fredun Pharmaceuticals Limited annual revenue and profit?
For FY26, Fredun Pharmaceuticals Limited reported full-year revenue of ₹633 cr and net profit of ₹32.62 cr, with EPS of ₹0.00.
How many quarterly results has FREDUN declared recently?
Past results dates for FREDUN will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
